DnB Asset Management’s MiNK Therapeutics INKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$552K Sell
43,960
-11,182
-20% -$127K ﹤0.01% 750
2026
Q2
$645K Buy
+55,142
New +$642K ﹤0.01% 714

Other funds holding INKT

DnB Asset Management's INKT Position: Q3 2026 in Review

DnB Asset Management reduced its MiNK Therapeutics (INKT) stake by 20% in Q3 2026, selling an estimated $127K and leaving 43,960 shares worth $552K. The position accounts for ﹤0.01% of the portfolio, ranked #750.

DnB Asset Management first reported a position in INKT in Q2 2026 and has held it in 2 quarters since. The position peaked at $645K in Q2 2026. 26 funds tracked by Wall St. Rank hold INKT as of Q3 2026.

  • DnB Asset Management held 43,960 shares of MiNK Therapeutics worth $552K as of Q3 2026.
  • DnB Asset Management sold 11,182 MiNK Therapeutics shares in Q3 2026, an estimated $127K.
  • MiNK Therapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q3 2026, its #750 holding.
  • DnB Asset Management first reported a position in MiNK Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • DnB Asset Management's MiNK Therapeutics position peaked at $645K in Q2 2026.
  • 26 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q3 2026.

Based on DnB Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.